Adjuvant systemic therapy options are anti-PD-1 therapy (nivolumab for resected stage IIIB-IV NED [I, A; ESMO-MCBS v1.1 score: no evaluable benefit] or pembrolizumab for resected stage III [I, A; ESMO-MCBS v1.1 score: A]) or dabrafenib–trametinib for patients with resected stage III BRAF V600E-mutated melanoma [I, A; ESCAT score: I-A]. The gene discussed is PDCD1; the disease is melanoma.